Elderly Patients With Acute Coronary Syndromes Managed Without Revascularization
Author(s) -
Matthew T. Roe,
Shaun G. Goodman,
E. Magnus Ohman,
Susanna R. Stevens,
Judith S. Hochman,
Shmuel Gottlieb,
Felipe A. Martínez,
Anthony J. Dalby,
William E. Boden,
Harvey D. White,
Dorairaj Prabhakaran,
Kenneth J. Winters,
Philip E. Aylward,
JeanPierre Bassand,
Darren K. McGuire,
Diego Ardissino,
Keith A.A. Fox,
Paul W. Armstrong
Publication year - 2013
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.113.002303
Subject(s) - medicine , prasugrel , clopidogrel , myocardial infarction , timi , hazard ratio , cardiology , clinical endpoint , population , aspirin , acute coronary syndrome , percutaneous coronary intervention , randomized controlled trial , confidence interval , environmental health
Dual antiplatelet therapy in older versus younger patients with acute coronary syndromes is understudied. Low-dose prasugrel (5 mg/d) is recommended for younger, lower-body-weight patients and elderly patients with acute coronary syndromes to mitigate the bleeding risk of standard-dose prasugrel (10 mg/d).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom